activity from proenzyme forms, whereas activation of components C4 and C3 produces fragments carrying labile binding sites, allowing the binding of complement proteins to membranes or other proteins to occur. The reaction is a cascade-type system, in which one active component-C1 molecule can activate many component-C3 molecules; active component C1 can also transfer from site to site. The available data on classical pathway components are shown in Table 1 .
The alternative pathway until recently was ill-defined. However, as a result of considerable effort in the last three years, a tentative scheme for this pathway can be proposed (Scheme 3). Recent reviews including information on this system are those by Fearon & Austen (1976) and Fothergill &Anderson (1978) . This pathway is activated by certain immunoglobulins, such as immunoglobulin A, that do not activate the classical pathway, and by various polysaccharides, such as bacterial endotoxin, zymosan from yeast cell walls and suspensions of inulin. It requires the presence of Mgz+ only. The early events in this system are still poorly understood but appear to involve a component known as initiating factor (IF), which may be immunoglobulin-like in character (Davis et al., 1977) . This pathway is more complex because it involves component C3 at two points. First, an active complex of initiating factor, factor B and component C3
Generation of component-C3-activating enzymes ( A A Scheme 2. Initial stages of the classical pathway for the activation of complement A, Antigenic site on cell; A , antibody; -, enzymic site; ----+, enzymic activity. C1, C2 etc., proenzyme forms of complement components; C1, C2a etc., active enzymes.
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Activating enzymes
Inactivating enzymes is formed in the presence of a small-molecular-weight proteinase, factor D. This complex, itself containing component C3, then activates further component C3 in a similar fashion to the classical pathway, the catalytic component being factor B. If the fragment C3b produced is deposited on a surface, in the presence of further factors B and D, more component C3 can be activated to form clumps of bound fragment C3b. The data available on components of the alternative pathway are shown in Table 2 .
(ii) Stage 2. The actual activation of component C3 is by proteolytic cleavage. Component C3 is a protein of two disulphide-bridged polypeptide chains (Scheme 4). Activation consists of the removal of a small fragment, C3a, from the N-terminal region of the a-chain. Enzymic inactivation of the fragment C3b is also by removal of a further small fragment, C3d, from the same chain.
(iii) Stage 3. The terminal components of complement are designated components C5, C6, C7, C8 and C9, acting consecutively.
In the case of activation by the classical pathway, the complex C,4,2,3 cleaves components C5 (a very similar molecule to component C3) into two fragments. The large fragment C5b becomes membrane-bound, the components C6-C9 complex with fragment C5b and cytolysis can occur. In the case of the alternative pathway, the complex containing (C3b)"B can directly activate component C5 as above. However, the stability of the component-C5-converting enzyme is markedly enhanced by the binding of a further component, known as properdin. 
Biological activities
Complement was first described as a heat-labile factor capable of acting together with antibody in the lysis of bacteria. Although cytolysis is probably the most widely known aspect of complement activity, the involvement of complement components in many different biological phenomena has been demonstrated (Table 3) .
(i) Cytolysis. This very dramatic effect of complement is the only activity requiring all the terminal components C5-C9 (see reviews by Humphrey & Dourmashkin, 1969; Dourmashkin et al., 1972) . It has been observed with erythrocytes, mammalian nucleated cells, such as Krebs ascites cells, rat peritoneal mast cells and Chinese-hamster lung cells (Shipley et al., 1971) , platelets (Polley & Nachman, 1975) , Gram-negative bacteria, the coat of avian infectious bronchitis virus and suspensions of bacterial lipopolysaccharide.
The end result of the binding of components C5-C9 is the formation of lesions allowing the passage of ions and small molecules. Subsequent distortion then allows the efflux of macromolecules (Green et al., 1959a,b) . Characteristic 'holes', about lOnm in diameter, with an electron-lucent ring of 2.5 nm, can be observed by electron microscopy. Although a correlation between the number of 'holes' and the calculated number of sites of damage has been made (Borsos et a/., 1964; Humphrey & Dourmashkin, 1969) , freezefracture techniques suggest that the 'holes' do not penetrate the full thickness of the lipid bilayer (Iles et al., 1973; Bhakdi et al., 1974) . Moreover, with liposomes, Kataoka et ( I / . (1973) found no correlation between the appearance of 'holes' and the release of contents.
The nature of the damage suffered by the membrane is not known. Complementmediated alterations of membrane proteins have been reported (Kniifermann et ul., 1971 ; Zimmerman & Miiller-Eberhard, 1973) . However, proteolysis is unlikely to be responsible for the formation of lesions, as these can be formed equally well on pure lipid liposomes (Inoue & Kinsky, 1970; Kinsky, 1972) . Phospholipase activity has not been detected (Inoue & Kinsky, 1970; Lachmann eta/., 1973) . Two further mechanisms have been proposed. One is the formation of hydrophilic channels through the membrane. Evidence for possible insertion of complement components into the membrane has been obtained by several authors (Bhakdi et af., 1975; Hammer et a/., 1975 Hammer et a/., , 1977 Miiller-Eberhard, 1975; Kolb & Miiller-Eberhard, 1976) . However, the freeze-fracture experiments mentioned above tend to discount the formation of a completely transmembrane channel. The second hypothesis is that the terminal components exert a detergent-like effect on the membrane (Kinsky, 1972) , causing a rearrangement of membrane structure. Such a redisposition of membrane components is substantiated by the freeze-fracture experiments. Moreover, a major rearrangement of membrane lipids has been reported to occur during complement lysis (Giavedoni & Dalmasso, 1976) , and displacement of membrane phospholipid has been observed (Tnoue et al., 1977) .
Changes in membrane properties have also been monitored by a decrease in deformability correlated with binding of component C3 (Durocher et a/., 1975) , nonosmotic swelling after the addition of component C9 (Valet & Opferkuch, 1975) and increased ion-permeability of lipid bilayers after the addition of components C5-C9 (Michaels et al., 1976) .
(ii) Modulation of the effects of immune complexes. The distribution of immune complexes in the body can be markedly affected by complement. First, the size of immune complexes can be dramatically increased by the binding of complement components, leading to their removal by the reticuloendothelial system, or deposition in the kidney or joints. Secondly, the localization of aggregated immunoglobulin G and, presumably, complexes to the germinal areas of the spleen requires component C3 (Papamichail et al., 1975) . Localization of antibody-antigen complexes to splenic lymphoid follicles may also be important in antibody production, as Klaus & Humphrey (1977) have shown that decomplementation inhibits the formation of B-lymphocyte memory cells.
Probably the most important function of complement is the mediation of the binding of immune complexes to various cell types. Complement receptors have been clearly demonstrated on primate erythrocytes, on non-primate platelets and on phagocytes and lymphocytes (see Henson, 1972) . Binding occurs by a stable site on fragments C3b (Nishioka & Linscott, 1963) and C4b (Cooper, 1969) . Depending on the cell type involved, the binding of complexes can produce several effects, as follows.
(a) Immune adherence to erythrocytes and phagocytes. Binding of complexes to receptors on erythrocytes greatly increases phagocytosis of the complex, resulting in more rapid engulfment of bacteria and viruses (Nelson, 1953 (Nelson, ,1956 Robineaux &Nelson, 1955) . Binding of complexes directly to complement receptors on phagocytic cells also potentiates phagocytosis (Gigli & Nelson, 1968; Wellek et al., 1975) . Phagocytes are attracted to the site of complement activation by the small fragments C3a and C5a and the complex C5,6,7, all of which are chemotactic agents.
Binding of complement also stimulates phagocytes to release lysosomal enzymes selectively (Go1dstein etal., 1973; Ward & Zvaifler, 1973; Schorlemmer & Allison, 1976) , and causes increased spreading of niacrophages and intense ruffling of the cell membrane .
(6) Binding to lymphocytes. B lymphocytes have receptors for fragments C3b, C3d and C4b (reviewed by Nussenzweig, 1974) . Such receptors might be of prime importance in the production of antibody. Certain authors (Dukor & Hartmann, 1973; Dukor et al., 1974) suggested that complement might provide the second signal required together with antigen for the production of antibodies. However, most recent work tends to discount this theory (Feldmann & Pepys, 1974; Pepys, 19746; Pryjma et a/., 1974;  Bitter-Suermann et a/., 1975), especially as a T-lymphocyte-independent response can be obtained in the absence of component C3 (Pryjma & Humphrey, 1975) . Antibody responses requiring the participation of T lymphocytes may possibly require the participation of complement (Feldmann & Pepys, 1974; Pepys, 19746) , perhaps in bringing together the two subsets of lymphocytes and the macrophages required for this response (Pepys, 1 9 7 4~; Arnaiz-Villena & Roitt, 1975) . At variance with this are reports of T-lymphocyte-dependent responses in the absence of complement (Waldmann & Lachmann, 1975) and normal antibody concentrations in a patient completely deficienr in component C3 (Alper et al., 1976) .
Complement has also been suggested as being responsible for the switch-over from immunoglobulin M production to immunoglobulin G production during the course of an immune response (Pepys, 19746; Nielsen & White, 1974) and in the induction of immunoglobulin E production (Pepys et af., 1977) .
Many other lymphocyte responses seem to be affected by complement. Cell-bound component C4 appears to be necessary for mixed lymphocyte reactions and mitogenic responses (Ferrone et a/., 1976) . Binding to fragment C3b results in the release of lymphokines of various types (O'Neill et al., Mackler et al., 1974; Sandberget al., 1975) and directly stimulates DNA synthesis (Hartmann & Bokisch, 1975) .
Lymphoid cells are very effective at destroying antibody-coated target cells (see Perlmann & Holm, 1969) ; the efficiency in some cases can be greatly increased by added target-cell bound complement Lustig & Bianco, 1976; Rouse et al., 1977) . This probably results from increased binding of the complex to the effector cell (Eden et al., 1973a ; Theofilopoulos et a/., 1974; Scornik & Drewinko, 1975) . Such an effector pathway is important in that it is not inhibited by physiological concentrations of immunoglobulin G, whereas the same type of cytolysis in the absence of complement is (Scornik, 1976; Barkas & Al-Khateeb, 1978) .
Finally, complement also exerts a regulatory role in determining the length of time complexes remain associated with lymphocytes. Low concentrations of complement have been shown to enhance the binding of complexes to lymphocytes, whereas high concentrations cause release. I n vivo this results in an initial rapid binding to cells, followed by rapid release into the circulation of modified antibody-antigen complex that is incabable of further binding to lymphocytes (Eden et al., 19736; Miller et al., 1973; Miller & Nussenzweig, 1975~) . Precipitated complexes appear to be solubilized by a similar mechanism (Miller & Nussenzweig, 197%) ; this may serve as a protective mechanism against the deposition of immune complexes (Czop & Nussenzweig, 1976) .
(c) Binding to platelets. In certain species, such as the rabbit, a mechanism exists for complement-dependent binding of complexes to platelets. This can result in either selective release of granule contents or total lysis of the platelet. depending on whether the complex is particulate or not (Henson & Cochrane, 1969; Henson, 1970) . Human platelets bind complexes in the absence of complement, but, in the presence of plasma, exhibit a biphasic response, the first phase being complement-independent, resulting in the release of 5-hydroxytryptamine (serotonin), and the second phase being complement-dependent, resulting in the aggregation of the platelets and a further release of granule contents. Zymosan can also produce this second release phase (Pfueller & Liischer, 1974a,b; Zucker etal., 1974) .
(iii) Inactivation o f bacterial lipopolysaccharide and neutralization of viruses. Bacterial lipopolysaccharide is reported to be inactivated by a detergent-like activity of component C5 (Johnson et a[., 1972) .
Viruses sensitized with immunoglobulin M antibodies can be neutralized by the sequential addition of components C1-C3 (Daniels et a[. Linscott & Levinson, 1969; Notkins, 1971 ; Oldstone et a/., 1974), whereas immunoglobulin G-sensitized viruses are less affected (Schrader & Muschel, 1975) . Virally infected cells can also be destroyed (reviewed by Porter, 1971) ; the antibody-directed killing of such cells by lymphocytes is enhanced by the presence of complement (Rouse et a[., 1977) .
Recent interesting developments are the reports of lysis of RNA tumour viruses by human serum containing the complete complement system (Welsh et al., 1975) . Type C virus is reported to be lysed by serum both from primates and from non-primates (Sherwin eta/., 1978) . However, these systems do not appear to require the presence of antibody.
(iv) Implications in cancer. Some evidence exists for activation of the complement system during tumour development. Antibody and component C3 have been shown
Vol. 6 to be present on tumour tissues (hie et al., 1974) . The inability of the complement system to destroy the tumour does not appear to be due to a low density of antigenic sites , as resistant tumour cells bind complement as efficiently as do non-resistant strains (Yu et al., 1975; .
Correlations between inhibition of, or absence of, complement activity and tumour development have been made. Increased concentrations of the natural inhibitor of component C1 have been found in the serum of cancer patients (Bach-Mortensen et a/., 1975; Spitzer et a/., 1975) ; the inhibitor has also been detected on the tumour cell (Osther & Linnemann, 1973; Osther, 1974; Bach-Mortensen et al., 1975) . Deficiency of component C5 in AKR mice has been implicated in the spontaneous development of leukaemia associated with this strain, and with impaired interferon activity (Kassel et a/., 1973) . Certain carcinogens impair the synthesis of components C4 and C2 (Colten & Borsos, 1974) . Tumour cells liberate a substance capable of inactivating chemotactic factors (Brozma & Ward, 1975) .
Conversely, certain anti-tumour drugs have been found to activate the complement system (Okuda et al., 1972) , and others appear to render the tumour cell more susceptible to the action of complement (Segerling et al., 1975a,b) . The anti-tumour agent Corynebacterium parvum activates complement in vivo in cancer patients (Birani et al., 1976) .
(v) Anuphylatoxins and kinins. In addition to their chemotactic activity, the small fragments C3a and C5a possess potent anaphylatoxin activity, liberating histamine from mast cells and contracting smooth muscle. A C-terminal arginine residue is essential for the activity (Bokisch & Miiller-Eberhard, 1970) . Both the direct binding of fragment C3a to rat mast cells (Ter Laan et al., 1974) and the direct release of histamine by fragments C3a and C5a (Johnston et al., 1975) have been demonstrated. The amino acid sequence of fragment C3a has been published (Hugli, 1975) .
During activation of the classical pathway, a kinin is generated. This activity has usually been ascribed to a fragment of component C2 (Klemperer et al., 1969) . However, the effect is not seen in a patient completely deficient in component C3, i.e. deficient in a complement protein later in the chain than component C2 (Alper et al., 1976) .
(vi) Coagulation and Jibrinolysis. A complement-dependent coagulation pathway has been demonstrated (Zimmerman & Muller-Eberhard, 1971 ). Deficiency of component C6 in rabbits results in impaired coagulation , whereas a similar defect in man does not (Leddy et al., 1973; Heusinkveld et al., 1974) . This probably results from the sensitivity of rabbit platelets to lysis by complement, releasing platelet factor 3 and promoting coagulation, whereas human platelets are not susceptible (Zimmerman & Kolb, 1976) .
Lysis of diluted blood clots is reported to require components C4 and C3 (Taylor & Muller-Eberhard, 1967; Schreiber & Austen, 1974) .
Control
With a system potentially capable of producing such drastic effects, mention must be made of the various safeguards built into the system to prevent the accidental triggering of complement activation and to contain the activity spatially and temporally.
Probably the most important regulatory effect is the lability of the binding sites generated at various steps (see Muller-Eberhard, 1969 . These have half-lives of the order of seconds or less; if binding does not occur in this space of time, the component becomes inactivated. Certain of the intermediates also have half-lives of a few minutes at 37°C.
Degradation by plasma proteinases and phagocytosis may also function as control mechanisms. The rates of catabolism of complement proteins are quite high, being 0.7-2.2 :
< of the plasma pool/h for several components.
Finally, as shown in Scheme 5, serum inhibitors exist for many of the activated components. Inhibition of enzyme c l is stoicheiometric, whereas the other inhibitors act enzymically. 
Conclusion
As a result of considerable interest over recent years, the actual mechanisms of the complement system have been worked out. Interest has now moved to the more complex field of a n understanding of the biological activities of complement, resulting in the discovery of complex interrelationships and interreactions between complement and both the fluid-phase systems of blood, such as fibrinolysis, coagulation and kinin generation, and cells of many types. Especially fascinating is the number of ways in which Complement is involved in defending the body against infections, by direct lysis of antibody-coated bacteria, by enhancement of antibody-dependent cellular cytotoxicity, by removal of complexes by immune adherence and enhanced phagocytosis, by direct stimulation of lymphocytes and possibly by involvement in the actual production of antibodies.
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